
- Oncology NEWS International Vol 5 No 1
- Volume 5
- Issue 1
Physicians Have Input Into HCFA, Pennsylvania Blue Shield Medical Policies
PITTSBURGH--Physicians in Pennsylvania play a "very heavy" role in medical policy decisions for the Health Care Financing Administration (HCFA) and Pennsylvania Blue Shield, Brent O'Connell, MD, said at the Association of Community Cancer Center's 1995 On-cology Symposium.
PITTSBURGH--Physicians in Pennsylvania play a "very heavy"role in medical policy decisions for the Health Care FinancingAdministration (HCFA) and Pennsylvania Blue Shield, Brent O'Connell,MD, said at the Association of Community Cancer Center's 1995On-cology Symposium.
Dr. O'Connell is vice president of Medical Affairs at PennsylvaniaBlue Shield, the nation's largest Medicare Part B carrier. PennsylvaniaBlue Shield handles 400,000 Medicare claims each day for Pennsylvania,New Jersey, Delaware, Maryland, the District of Columbia, andnorthern Virginia.
For Medicare, medical policies are developed both by HCFA andthe local carriers, he explained. Sometimes, instead of settinga national policy for a certain procedure, the agency gives localcarriers some guidelines and requests that they develop the policyand use it for their claims, he said.
Pennsylvania Blue Shield develops medical policy for both itsMedicare and private insurance business through input from nearly500 paid consultants throughout its Medicare service area.
For HCFA policy, the carrier advisory committee assists in thedevelopment of the final policy. Blue Shield policy has to beapproved first by its medical affairs committee, made up of physicianselected by their peers across Pennsylvania. The policy then goesto the board of directors, and half of the board members are physicians.
"Your peers have a lot to do with the development of ourpolicies, for example, decisions about coverage for a certainprocedure," Dr. O'Connell said. "When we develop policy,we are responding to you."
Articles in this issue
almost 30 years ago
HCFA Reevaluations May Affect Chemo Administration Cost Codesalmost 30 years ago
Breast Cancer Info Now on Internetalmost 30 years ago
HDC/ABMT Has Benefits in Multiple Myelomaalmost 30 years ago
Clinical Trial to Study MoAb 17-1A as An Adjuvant to Colon Cancer Therapyalmost 30 years ago
Reporting of Study Comparing Casodex, Eulexin Is Questionedalmost 30 years ago
Limits on Tamoxifen Duration Questionedalmost 30 years ago
ACRO Forecasts Radiologist Surplusalmost 30 years ago
Potency Status Before RT, Not Dose, Determines Post-RT Functionalmost 30 years ago
Dr. Klausner Outlines Goals for NCIalmost 30 years ago
Difficulties in Translating Relative Risks Into Absolute RiskNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.